GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Gerresheimer AG (XTER:GXI) » Definitions » Debt-to-EBITDA

Gerresheimer AG (XTER:GXI) Debt-to-EBITDA : 3.44 (As of Feb. 2024)


View and export this data going back to 2007. Start your Free Trial

What is Gerresheimer AG Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Gerresheimer AG's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Feb. 2024 was €465 Mil. Gerresheimer AG's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Feb. 2024 was €651 Mil. Gerresheimer AG's annualized EBITDA for the quarter that ended in Feb. 2024 was €325 Mil. Gerresheimer AG's annualized Debt-to-EBITDA for the quarter that ended in Feb. 2024 was 3.44.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Gerresheimer AG's Debt-to-EBITDA or its related term are showing as below:

XTER:GXI' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 2.04   Med: 3.3   Max: 3.86
Current: 2.74

During the past 13 years, the highest Debt-to-EBITDA Ratio of Gerresheimer AG was 3.86. The lowest was 2.04. And the median was 3.30.

XTER:GXI's Debt-to-EBITDA is ranked worse than
70.05% of 434 companies
in the Medical Devices & Instruments industry
Industry Median: 1.21 vs XTER:GXI: 2.74

Gerresheimer AG Debt-to-EBITDA Historical Data

The historical data trend for Gerresheimer AG's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gerresheimer AG Debt-to-EBITDA Chart

Gerresheimer AG Annual Data
Trend Nov14 Nov15 Nov16 Nov17 Nov18 Nov19 Nov20 Nov21 Nov22 Nov23
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.61 3.48 3.86 3.59 2.58

Gerresheimer AG Quarterly Data
May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.30 2.56 2.71 2.20 3.44

Competitive Comparison of Gerresheimer AG's Debt-to-EBITDA

For the Medical Instruments & Supplies subindustry, Gerresheimer AG's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Gerresheimer AG's Debt-to-EBITDA Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Gerresheimer AG's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Gerresheimer AG's Debt-to-EBITDA falls into.



Gerresheimer AG Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Gerresheimer AG's Debt-to-EBITDA for the fiscal year that ended in Nov. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(382.813 + 658.495) / 403.89
=2.58

Gerresheimer AG's annualized Debt-to-EBITDA for the quarter that ended in Feb. 2024 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(465.434 + 651.36) / 324.696
=3.44

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Feb. 2024) EBITDA data.


Gerresheimer AG  (XTER:GXI) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Gerresheimer AG Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Gerresheimer AG's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Gerresheimer AG (XTER:GXI) Business Description

Address
Klaus-Bungert-Strasse 4, Duesseldorf, NW, DEU, 40468
Gerresheimer AG provides medicine packaging, drug delivery devices, and solutions with a product range for pharma, health, well-being, and biotech. The firm operates in three segments: The plastics and devices segment consists of products for simple and safe drug delivery along with packaging for liquid and solid medicines, The primary packaging glass segment produces glass packaging products for the pharma and cosmetics industries also for food and beverage industry and The advanced technologies segment works on technical and digital solutions to improve the therapy outcome for patients. The company generates the majority of its revenue in Europe, with sales in Germany contributing the major proportion of any country.
Executives
Dietmar Siemssen Board of Directors
Dr. Lukas Burkhardt Board of Directors
Andrea Abt Supervisory Board

Gerresheimer AG (XTER:GXI) Headlines

No Headlines